T. Rowe Price Associates’s GALENA BIOPHARMA INC COM RXII Stock Holding History

T. Rowe Price Associates’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-59,906	Closed	-$21K	–	2606
2016 Q3	$21K	Sell	59,906 -994	-2%	-$348	﹤0.01%	2519
2016 Q2	$28K	Buy	60,900 +1,000	+2%	+$460	﹤0.01%	2499
2016 Q1	$81K	Hold	59,900	–	–	﹤0.01%	2436
2015 Q4	$88K	Buy	59,900 +500	+0.8%	+$735	﹤0.01%	2438
2015 Q3	$94K	Hold	59,400	–	–	﹤0.01%	2417
2015 Q2	$101K	Hold	59,400	–	–	﹤0.01%	2458
2015 Q1	$83K	Sell	59,400 -25,000	-30%	-$34.9K	﹤0.01%	2486
2014 Q4	$127K	Buy	84,400 +38,600	+84%	+$58.1K	﹤0.01%	2443
2014 Q3	$94K	Hold	45,800	–	–	﹤0.01%	2478
2014 Q2	$140K	Buy	+45,800	New	+$140K	﹤0.01%	2426

T. Rowe Price Associates's RXII Position: Q4 2016 in Review

T. Rowe Price Associates sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 59,906 shares — an estimated $21K sold.

T. Rowe Price Associates first reported a position in RXII in Q2 2014 and held it in 10 quarters. The position peaked at $140K in Q2 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

T. Rowe Price Associates reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
T. Rowe Price Associates sold 59,906 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $21K.
T. Rowe Price Associates first reported a position in GALENA BIOPHARMA INC COM in Q2 2014 and held it in 10 quarters.
T. Rowe Price Associates's GALENA BIOPHARMA INC COM position peaked at $140K in Q2 2014.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on T. Rowe Price Associates's 13F filing for Q4 2016, filed 14 Feb 2017.